NZ592261A - Novel immunotherapy against neuronal and brain tumors - Google Patents

Novel immunotherapy against neuronal and brain tumors

Info

Publication number
NZ592261A
NZ592261A NZ59226108A NZ59226108A NZ592261A NZ 592261 A NZ592261 A NZ 592261A NZ 59226108 A NZ59226108 A NZ 59226108A NZ 59226108 A NZ59226108 A NZ 59226108A NZ 592261 A NZ592261 A NZ 592261A
Authority
NZ
New Zealand
Prior art keywords
brain tumors
immunotherapy against
against neuronal
novel immunotherapy
peptide
Prior art date
Application number
NZ59226108A
Other languages
English (en)
Inventor
Oliver Schoor
Norbert Hilf
Toni Weinschenk
Claudia Trautwein
Steffen Walter
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08005889.4A external-priority patent/EP2105501B1/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of NZ592261A publication Critical patent/NZ592261A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/02—Sulfotransferases (2.8.2)
    • C12Y208/02011—Galactosylceramide sulfotransferase (2.8.2.11)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ59226108A 2007-07-27 2008-07-25 Novel immunotherapy against neuronal and brain tumors NZ592261A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07014797 2007-07-27
US95316107P 2007-07-31 2007-07-31
EP08005889.4A EP2105501B1 (en) 2008-03-27 2008-03-27 Novel immunotherapy against neuronal and brain tumors
NZ582824A NZ582824A (en) 2007-07-27 2008-07-25 Novel immunotherapy against neuronal and brain tumors

Publications (1)

Publication Number Publication Date
NZ592261A true NZ592261A (en) 2012-09-28

Family

ID=39720257

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ59226108A NZ592261A (en) 2007-07-27 2008-07-25 Novel immunotherapy against neuronal and brain tumors
NZ582824A NZ582824A (en) 2007-07-27 2008-07-25 Novel immunotherapy against neuronal and brain tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ582824A NZ582824A (en) 2007-07-27 2008-07-25 Novel immunotherapy against neuronal and brain tumors

Country Status (21)

Country Link
US (6) US9175040B2 (enExample)
EP (2) EP2183361B1 (enExample)
JP (2) JP6008461B2 (enExample)
KR (2) KR101317989B1 (enExample)
CN (2) CN101809148B (enExample)
AU (1) AU2008281015B2 (enExample)
BR (1) BRPI0813621A2 (enExample)
CA (2) CA2863010C (enExample)
CY (1) CY1117115T1 (enExample)
DK (2) DK2660248T3 (enExample)
EA (2) EA034800B1 (enExample)
ES (2) ES2546610T3 (enExample)
HR (2) HRP20150820T1 (enExample)
HU (1) HUE027524T2 (enExample)
MX (1) MX2010001086A (enExample)
NZ (2) NZ592261A (enExample)
PL (2) PL2183361T3 (enExample)
PT (2) PT2660248E (enExample)
RS (2) RS54204B1 (enExample)
SI (2) SI2183361T1 (enExample)
WO (1) WO2009015843A1 (enExample)

Families Citing this family (30)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
RS54204B1 (sr) 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora mozga
US8530429B2 (en) * 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US8603485B2 (en) * 2011-01-05 2013-12-10 Wisconsin Alumni Research Foundation Bystander immune suppression as a predictor for response to a vaccine
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) * 2013-12-04 2017-07-21 č‹å·žäø­čµ¢åŒ»ē–—ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§č„‘čƒ¶č“Øē˜¤č‚æē˜¤ę ‡åæ—ē‰©åŠå…¶åŗ”ē”Ø
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CR20210232A (es) 2015-03-17 2022-06-24 Immatics Biotechnologies Gmbh NUEVOS PƉPTIDOS Y NUEVA COMBINACIƓN DE PƉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CƁNCER DE PƁNCREAS Y OTROS TIPOS DE CƁNCER (Divisional 2017-0419)
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PT3319985T (pt) 2015-07-06 2021-01-06 Immatics Biotechnologies Gmbh Novos pĆ©ptidos e combinaĆ§Ć£o de pĆ©ptidos para uso em imunoterapia do cancro do esĆ³fago e outros cancros
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
IL292864A (en) * 2015-08-28 2022-07-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
JP7114477B2 (ja) 2015-12-16 2022-08-08 悰ćƒŖćƒƒćƒˆć‚¹ćƒˆćƒ¼ćƒ³ 惐悤ć‚Ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ꖰē”ŸęŠ—åŽŸć®ē‰¹å®šć€č£½é€ ć€ćŠć‚ˆć³ä½æē”Ø
EP3429618B1 (en) 2016-03-16 2024-02-21 Amal Therapeutics SA Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
AU2017305396A1 (en) * 2016-08-02 2019-02-21 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor
KR20190057345A (ko) 2016-09-21 2019-05-28 ģ•„ė§ ķ…Œė¼ķ“Øķ‹±ģŠ¤ ģ—ģŠ¤ģ—ģ“ ģ•” ģ¹˜ė£Œė„¼ ģœ„ķ•œ, ģ„øķ¬ ķˆ¬ź³¼ ķŽ©ķƒ€ģ“ė“œ, ė©€ķ‹° ģ—ķ”¼ķ† ķ”„ ė° tlr ķŽ©ķƒ€ģ“ė“œ ģž‘ģš©ģ œė„¼ ķ¬ķ•Øķ•˜ėŠ” ģœµķ•©ģ²“
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
CR20210160A (es) * 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh PƩptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cƔncer (divisional de solicitud 2019-0508)
CN111465989B (zh) 2017-10-10 2024-06-25 ē£ØēŸ³ē”Ÿē‰©å…¬åø ä½æē”Øēƒ­ē‚¹čæ›č”Œēš„ę–°ęŠ—åŽŸé‰“别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
AU2020286756A1 (en) 2019-06-06 2022-01-27 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
US20230055337A1 (en) * 2020-02-24 2023-02-23 The Regents Of The University Of California Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
WO2023049733A2 (en) * 2021-09-21 2023-03-30 The University Of Chicago Methods and composition using patient-derived autologous neoantigens for treating cancer

Family Cites Families (42)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
JPS6081130A (ja) * 1983-10-07 1985-05-09 Fujisawa Pharmaceut Co Ltd ꊗļ½ˆļ½Œļ½āˆ’ļ½ļ¼’ęŠ—ä½“ćŠć‚ˆć³ćć‚Œć‚’ē”£ē”Ÿć™ć‚‹ćƒć‚¤ćƒ–ćƒŖ惉āˆ’ćƒž
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5651972A (en) * 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
US5202666A (en) * 1991-01-18 1993-04-13 Net/Tech International Inc. Method and apparatus for enhancing hygiene
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
EP0819171A1 (en) * 1995-04-07 1998-01-21 The Regents Of The University Of California Antibodies for the detection of hla-g
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-Ī± and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE19739089A1 (de) * 1997-09-06 1999-03-11 Hella Kg Hueck & Co Scheinwerfer fĆ¼r Fahrzeuge
JP2001516766A (ja) * 1997-09-19 2001-10-02 惇悤惊āˆ’ćƒ•ć‚”ćƒ¼ćƒćƒ¼ ć‚­ćƒ£ćƒ³ć‚µćƒ¼ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒćƒ„ćƒ¼ćƒˆļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ 免ē–«ååæœć®ē“°čƒžå†…ē™ŗē¾ęŠ—体仲介制徔
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
AU5284200A (en) * 1999-06-03 2000-12-28 Cold Spring Harbor Laboratory Substrate trapping protein tyrosine phosphatases
US6455026B1 (en) * 2001-03-23 2002-09-24 Agy Therapeutics, Inc. Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
US20030118585A1 (en) 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
JP2003012544A (ja) * 2001-03-27 2003-01-15 Kouji Egawa ē™Œäŗˆé˜²ćƒ»ę²»ē™‚剤
US20070082337A1 (en) * 2004-01-27 2007-04-12 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
US20050260132A1 (en) * 2001-10-17 2005-11-24 Daniel Chin Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
EP1451305A4 (en) * 2001-11-07 2005-10-05 Mannkind Corp EPITOPE SYNCHRONIZATION IN CELLS THAT HAVE ANTIGENS
WO2003042661A2 (en) * 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7236577B2 (en) * 2002-11-14 2007-06-26 International Business Machines Corporation Call screening system and method
KR100494979B1 (ko) * 2003-07-14 2005-06-14 ģ£¼ģ‹ķšŒģ‚¬ ģ •ģš°ģøķ„°ė‚“ģ…”ė‚  ģ”°ģ§ ģ ˆķŽø ė³“ķ˜ø ė° ķ•“ģƒė „ ģ¦ģ§„ģš© ģ•”ģƒ ģ»¤ė²„ ģŠ¬ė¦½, ź·øģ œģ”°ģš© ģ”°ģ„±ė¬¼, ź·øė”œė¶€ķ„° ģ œģ”°ėœ ģ»¤ė²„ģŠ¬ė¦½ģ„ źµ¬ė¹„ķ•œģŠ¬ė¼ģ“ė“œ źµ¬ģ”°ģ²“ ė° ź·ø ģ œģ”°ė°©ė²•
US7050785B2 (en) * 2003-12-08 2006-05-23 Research In Motion Limited Apparatus and method of explicit indication of call from emergency call centre
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-MolekĆ¼le bindende Tumor-assoziierte Peptide
US7231200B2 (en) * 2004-09-30 2007-06-12 Nevin Jenkins Personal emergency communication system
US7315736B2 (en) * 2004-09-30 2008-01-01 Jenkins Nevin C Personal emergency communication system
DE602005020046D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
SI1760089T1 (sl) 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
RS54204B1 (sr) * 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora mozga
EP2113253B1 (en) 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh ComposiciĆ³n de pĆ©ptidos tumor-asociados y relacionados con la vacuna contra el cĆ”ncer para el tratamiento de glioblastoma (GBM) y otros cĆ”nceres
US10046046B2 (en) * 2014-06-05 2018-08-14 Victoria Link Limited Amino sphingoglycolipid analogues

Also Published As

Publication number Publication date
AU2008281015A1 (en) 2009-02-05
CA2863010C (en) 2017-01-24
US20160175357A1 (en) 2016-06-23
MX2010001086A (es) 2010-04-09
PL2660248T3 (pl) 2015-11-30
EP2183361B1 (en) 2015-06-10
CA2694808C (en) 2015-10-13
US20230241111A1 (en) 2023-08-03
US11986497B2 (en) 2024-05-21
HK1191022A1 (en) 2014-08-29
US9175040B2 (en) 2015-11-03
RS54147B1 (sr) 2015-12-31
RS54204B1 (sr) 2015-12-31
NZ582824A (en) 2012-07-27
JP2013226145A (ja) 2013-11-07
AU2008281015B2 (en) 2012-07-26
JP6008461B2 (ja) 2016-10-19
KR101290892B1 (ko) 2013-07-31
CN101809148A (zh) 2010-08-18
EP2660248A1 (en) 2013-11-06
KR20120025014A (ko) 2012-03-14
US20190321405A1 (en) 2019-10-24
PT2660248E (pt) 2015-10-12
DK2183361T3 (en) 2015-07-27
HRP20150852T1 (hr) 2015-09-25
JP2010534464A (ja) 2010-11-11
WO2009015843A1 (en) 2009-02-05
EA034800B1 (ru) 2020-03-23
CA2863010A1 (en) 2009-02-05
BRPI0813621A2 (pt) 2017-05-09
EA201000209A1 (ru) 2011-02-28
HRP20150820T1 (xx) 2015-09-11
CY1117115T1 (el) 2017-04-05
US20200345777A1 (en) 2020-11-05
EP2660248B1 (en) 2015-06-10
CN101809148B (zh) 2014-07-16
PT2183361E (pt) 2015-09-11
DK2660248T3 (en) 2015-09-07
AU2008281015A2 (en) 2010-05-27
US20090123489A1 (en) 2009-05-14
CN103911358B (zh) 2017-03-01
EA029831B1 (ru) 2018-05-31
CN103911358A (zh) 2014-07-09
US20190076477A1 (en) 2019-03-14
HUE027524T2 (en) 2016-11-28
SI2660248T1 (sl) 2015-10-30
US10709735B2 (en) 2020-07-14
US11648276B2 (en) 2023-05-16
SI2183361T1 (sl) 2015-09-30
EA201791519A1 (ru) 2018-03-30
PL2183361T3 (pl) 2015-10-30
KR20100040874A (ko) 2010-04-21
US10434120B2 (en) 2019-10-08
KR101317989B1 (ko) 2013-10-14
JP5738348B2 (ja) 2015-06-24
ES2546610T3 (es) 2015-09-25
CA2694808A1 (en) 2009-02-05
EP2183361A1 (en) 2010-05-12
ES2543815T3 (es) 2015-08-24

Similar Documents

Publication Publication Date Title
NZ582822A (en) Novel immunogenic epitopes for immunotherapy
NZ627877A (en) Immunotherapy against several tumors including gastrointestinal and gastric cancer
NZ595792A (en) Antibodies specific to cadherin-17
PH12012502121A1 (en) Peptide conjugates of glp-1 receptor agonists and gastrin and their use
NZ610091A (en) Antibodies
MX2015000428A (es) Composiciones y metodos para regular celulas t car.
MY205540A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
MX354450B (es) Anticuerpos anti proteĆ­na accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
WO2014144666A3 (en) Methods and compositions related to t-cell activity
PH12014500483A1 (en) Anti-erbb3 antibodies and uses thereof
MX2008007286A (es) Ingenieria in vivo de superficie celular.
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
NZ716587A (en) Antibodies specific for claudin 6 (cldn6)
IN2012DN00446A (enExample)
GB2462020A (en) Systems, methods, and processes for use in treating subsurface formations
MY169644A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
NZ630536A (en) Therapeutic agent or prophylactic agent for dementia
WO2007117657A3 (en) Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
AU313995S (en) Toaster
SG10201407938TA (en) Agents for treating disease
MX337586B (es) Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta.
MX2014005351A (es) Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
MX2012008958A (es) Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
NZ584606A (en) An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO2008083326A3 (en) Targeting of ews-fli1 as anti-tumor therapy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 JUL 2015 BY ANNA STINES

Effective date: 20130416

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUL 2016 BY PAVIS EG

Effective date: 20150714

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUL 2017 BY PAVIS EG

Effective date: 20160715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUL 2018 BY PAVIS GMBH

Effective date: 20170713

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUL 2019 BY PAVIS GMBH

Effective date: 20180713

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUL 2020 BY PAVIS GMBH

Effective date: 20190717

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUL 2021 BY PAVIS GMBH

Effective date: 20200722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUL 2022 BY PAVIS PAYMENTS GMBH

Effective date: 20210714

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUL 2023 BY PAVIS PAYMENTS GMBH

Effective date: 20220712

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUL 2024 BY PAVIS PAYMENTS GMBH

Effective date: 20230714

LAPS Patent lapsed